

Alpha Mid-Year Report 2023


a snapshot of aMoon's investor additionality

Confidential & Internal



aMoon continues to support
it's portfolio companies
across all alpha domains:

87%
of aMG & aMV portfolio
27 out of 30*

41
differentiated support activities
yielding **impactful outcomes**



H1 2023 HIGHLIGHTS



METASIGHT <> Acumen.

The communications team at aMoon supported MetaSight through their **de-stealthening process**, helping them craft messages to stakeholder audiences to successfully get introduced to the market.

Through aMoon connections, **MetaSight was introduced to Acumen Strategies** a strategic communications consultant, for storytelling support. The communications team prepared MetaSight for media interviews, enhancing their ability to confidently share their technology's significance.

aMoon's support extended to PR and Placement efforts, with the team drafting a LinkedIn post announcing MetaSight's emergence from stealth, and assisting on the drafting of a press release highlighting their partnership with KSM to increase early detection of different diseases.

These collaborative efforts ensured that MetaSight's visionary technology was effectively communicated to the market.



omada <> PHIR

A recent milestone for Omada came with their participation in the **Provider Health Innovation Roundtable (PHIR)**, a collaborative initiative that brings together start-ups and regional health systems, to streamline and prioritize emerging solutions for partnerships.

Following Omada's onboarding event, in which they requested aMoon's assistance with introductions to Health Systems, we advised them to enter the curation process of PHIR. When they reached the last phase of selection but were not chosen to be part of the 10 featured companies, we offered them our "investor spotlight" (a privilege reserved for EHIR sponsors), that enabled them to **present to 10 leading health providers**. aMoon alpha team provided support to Omada before and during the event, both by providing them advisory sessions with PHIR experts to perfect their pitch, and by giving them onsite assistance to appeal to the interests of the provider representatives.

Omada's performance, together with aMoon's assistance, enabled them to **secure six matches from various US based providers**, and eventually earn the **Spring 2023 PHIR Traction Award**. 4 of these providers have progressed to deeper discussions.



BIOMED ISRAEL

Biomed Israel served as a valuable opportunity for us to **enhance our engagement with strategic partners and offer support to our portfolio companies through meaningful introductions.**

As a fund, we contributed to the conference through three key initiatives. In partnership with Credit Suisse, aMoon sponsored the speaker's dinner, enabling our portfolio companies **Nectin, MDClone, and Lyfegen** to attend and interact with Strategics executives. **Yaron** moderated the panel titled "Are Cancer Therapeutics Fulfilling the Promise?", providing a platform for our portfolio companies **Nectin** and **BioLogic Designs** to present before a broad audience of global investors and Strategics. Additionally, **Yael G.** took the lead in moderating the session "Facts and Myths on Ex-Liver Drug Delivery and New Horizons to Cure Rare Disorders", resulting in significant deal flow opportunities post-event.


Throughout the conference, **Yair, Yaron, Yael, Gur, Roy, Tamar, Vered, Osnat & Chaim**, met with senior delegations from a variety of global pharmaceutical companies such as **Gilead, Pfizer, Novartis, Roche, MSD, Daiichi, Debiophar, Dr. Reddy & Sanofi.**

aMoon efforts prior and throughout the conference led to meetings taking place between portfolio companies such as **MetaSight, MDClone, Nectin, Coltac, BioLogic Design, and Kahr** with strategies such as **Pfizer, MSD, Novartis, Gilead, and Sanofi.**



SNAPSHOT OF OUR NETWORK

Strength of connections by Affinity



OUR EVENTS

LAST EVENT

LEAP
Showcasing 1st cohort

We recently celebrated the end of our 13-week LEAP program, a journey of innovation and growth. Participants showcased exciting new initiatives, from cutting-edge AI systems to innovative neonatal care technology and a collaborative, data-driven platform.

Our event featured a panel of esteemed investors, including Renana Ashkenazi from Grove Ventures, Sam Cronin from Arkin Digital Health, Dr. Gal Noyman – Veksler from LionBird, and our own **Yaron**, who shared insights on the challenges that these companies will face on their path to success.

LEAP is a testament to our commitment at aMoon to foster the growth of the Israeli HealthTech ecosystem. Guided by top-tier investors, market experts, physicians, entrepreneurs, and executives, it aims to pave the way for the next wave of Israeli HealthTech startups.


The success of our first cohort wouldn't have been possible without the strong collaboration between **Beilinson Innovation, 8200Bio, Amazon Web Services (AWS)**, and our dedicated aMoon team, specifically **Ido** and **Ohad** for their unwavering commitment to making LEAP an enriching experience for all involved.

NEXT EVENT

J.P.Morgan
Healthcare Conference

8-11 January, 2024

We are starting to gear up for the JPM Healthcare Conference in San Francisco! This highly anticipated event provides us opportunities to enhance our relationships with Strategics, Bankers, and Funds, as well as assisting our portfolio companies by providing introductions. We also plan to host another CEO Network Gathering – pictures to follow...



Brought to you by aMoon alpha.

Have any thoughts or questions?
Contact the alpha team